Pulike announced that, following review by the Ministry of Agriculture and Rural Affairs, the Denaverine Hydrochloride Injection jointly declared by its wholly owned subsidiary Luoyang Huizhong Veterinary Medicine and other entities was approved as a new veterinary drug, and the issuance of the New Veterinary Drug Registration Certificate was publicized on September 14, 2026. The new veterinary drug is registered as Class II, with denaverine hydrochloride as the main ingredient. It is indicated for promoting soft tissue dilation of the birth canal and facilitating parturition in first-calf heifers, administered as a single intramuscular injection of 10 milliliters, used only once. The company stated that this product is a national Class II new veterinary drug.
Pulike Biological EngineeringWholly owned subsidiary's Denaverine Hydrochloride Injection approved as a national Class II new veterinary drug, adding a new product to its portfolio.
